Perifosine Enhances Prostate Cancer Radiosensitivity
Author Information
Author(s): Gao Yuanhong, Ishiyama Hiromichi, Sun Mianen, Brinkman Kathryn L, Wang Xiaozhen, Zhu Julie, Mai Weiyuan, Huang Ying, Floryk Daniel, Ittmann Michael, Thompson Timothy C, Butler E Brian, Xu Bo, Teh Bin S
Primary Institution: Department of Radiation Oncology, The Methodist Hospital Research Institute, Weill Cornell Medical College
Hypothesis
Does the combination of perifosine and radiation improve the treatment of prostate cancer?
Conclusion
Perifosine enhances prostate cancer radiosensitivity in vitro and in vivo.
Supporting Evidence
- CTPR had greater inhibitory effects on prostate cancer cell viability than either perifosine or radiation alone.
- A marked increase in prostate cancer cell apoptosis was noted in the CTPR group.
- In vivo, CTPR had greater inhibitory effects on the growth of xenografts compared with perifosine or radiation treatment alone.
Takeaway
Perifosine is a drug that helps make prostate cancer cells more sensitive to radiation, which can help treat the cancer better.
Methodology
The study used human prostate cancer cell lines and xenografts in mice to assess the effects of perifosine combined with radiation.
Limitations
The study did not achieve complete tumor regression and the effects may vary based on cancer type and treatment schedule.
Participant Demographics
Male Athymic Nude-Foxn1nu mice, 6 to 7 weeks old.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website